As of September 30, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $278.4 million. “Earlier this month, we announced bold plans for the future of Nkarta. This includes the expansion of our NK cell therapy pipeline into autoimmune disease, key anticipated updates in 2024, and the extension of our projected cash runway into 2026,” said Paul J. Hastings, President and CEO of Nkarta. “Our pipeline now has three clinical-stage NK cell therapy programs, each increasing our opportunity for success. Our strategy for advancing these programs centers on stringent capital allocation, rapid execution, and business prioritization.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NKTX:
- Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Nkarta to Participate at Upcoming Investor Conferences
- Nkarta price target lowered to $15 from $25 at Canaccord
- Nkarta price target lowered to $10 from $16 at H.C. Wainwright
- Nkarta upgraded to Strong Buy from Outperform at Raymond James